Measure Title: |
RELATING TO ACCESS TO TREATMENT FOR TERMINALLY ILL PATIENTS.
|
Report Title: |
Right-to-Try Act; Terminally Ill Patients; Investigational Drugs; Biological Products
|
Description: |
Beginning on January 1, 2025, permits manufacturers of investigational drugs or biological products to make these drugs and products available to terminally ill patients under certain conditions.
|
Companion: |
HB2024
|
Package: |
None
|
Current Referral: |
HHS, CPN/JDC
|
Introducer(s): |
CHANG, FEVELLA, HASHIMOTO, KIDANI, MORIWAKI, RICHARDS, SAN BUENAVENTURA
|
Act: |
|
Sort by Date | | Status Text |
1/17/2024 | S | Referred to HHS, CPN/JDC. |
1/17/2024 | S | Introduced and passed First Reading. |
1/10/2024 | S | Pending Introduction. |
S = Senate |
H = House |
D = Data Systems |
$ = Appropriation measure |
ConAm = Constitutional Amendment
Some of the above items require Adobe Acrobat Reader. Please visit
Adobe's download page
for detailed instructions.
SB2023